Management of Anemia of Chronic Disease in Patients with the Human Immunodeficiency Virus

Pharmacotherapy

Volumn 23, Issue 11, 2003, Pages 1475-1485

  Brokering, Kristi L ^a   Qaqish, Roula B ^a  

^a ST LOUIS COLLEGE OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; RECOMBINANT ERYTHROPOIETIN; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; ANGINA PECTORIS; ANIMAL; ANOREXIA; ANTIVIRAL ACTIVITY; BLOOD; BLOOD TRANSFUSION; CHRONIC DISEASE; CLINICAL TRIAL; COLD TOLERANCE; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MANAGEMENT; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; FATIGUE; HEADACHE; HEART FAILURE; HEART MURMUR; HEART PALPITATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMITTENT CLAUDICATION; IRRITABILITY; MUSCLE WEAKNESS; NAIL DISEASE; NAUSEA; PALLOR; PREVALENCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SLEEP DISORDER; SURVIVAL; SYNCOPE; TACHYCARDIA; TACHYPNEA; TINNITUS; VERTIGO;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANEMIA; ANIMALS; CHRONIC DISEASE; DISEASE MANAGEMENT; HIV INFECTIONS; HUMANS;

EID: 0142151532     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.14.1475.31949     Document Type: Review

References (50)

1. Coyle TE. Hematologic complications of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Med Clin North Am 1997;81:449-70.
2. Lee GR. Anemia: general aspects. In: Lee GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM, eds. Wintrobe's clinical hematology, 10th ed. Baltimore: Williams & Wilkins, 1999:897-901.
3. Sullivan PS, Hanson DL, Chu SY, Jones JL, Ward JW, for the Adult/Adolescent Spectrum of Disease Group. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood 1998;91:301-8.
4. Mocroft A, Kirk O, Barton SE, et al. Anemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. AIDS 1999;13:43-50.
5. Moore RD, Keruly JC, Chaisson RE. Anemia and survival in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:29-33.
6. Sullivan P. Associations of anemia, treatments for anemia and survival in patients with human immunodeficiency virus infection. J Infect Dis 2000;185(suppl 2):S138-42.
7. Moore RD. Human immunodeficiency virus infection, anemia and survival. Clin Infect Dis 1999;29:44-9.
8. Vamvakas E, Kaplan HS. Early transfusion and length of survival in acquired immune deficiency syndrome: experience with a population receiving medical care at a public hospital. Transfusion 1993;33:111-18.
9. Sloand E, Kumar P, Klein HG, Merritt S, Sacher R. Transfusion of blood components to persons infected with human immunodeficiency virus type 1: relationship to opportunistic infection. Transfusion 1994;34:48-53.
10. Fischl M, Galpin JE, Levine JD, et al. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med 1990;322:1488-93.
11. Henry DH, Beall GN, Benson CA, et al. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy: overview of four clinical trials. Ann Intern Med 1992;117:739-48.
12. Phair JP, Abels RI, McNeill MV, Sullivan DJ. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immununodeficiency syndrome. Arch Intern Med 1993;153:2669-75.
13. Balfour HH. Recombinant human erythropoietin for treatment of anemia in persons with AIDS not receiving zidovudine. Int J Antimicrob Agents 1997;8:189-92.
14. Revicki DA, Brown RE, Henry DH, McNeill MV, Rios A, Watson T. Recombinant human erythropoietin and health-related quality of life of AIDS patients with anemia. J Acquir Immune Defic Syndr 1994;7:474-84.
15. Abrams DI, Steinhart C, Frascino R. Epoetin alfa therapy for anemia in HIV-infected patients: impact on quality of life. Int J STD AIDS 2000;11:659-65.
16. Levine AM, Deyton LR, Saag MS. Weekly dosing with epoetin alpha in HIV-infected patients with anemia: interim data [abstr]. In: Program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy. San Francisco, CA, September 26-29, 1999. Washington, DC: American Society for Microbiology, 1999:504.
17. Saag MS, Levine AM, Leitz GJ, Bowers PJ. Once-weekly epoetin alfa increases Hgb and improves quality of life in anemic HIV-positive patients [abstr]. Clin Infect Dis 2001;33:1209.
18. Grossman H, Bowers P, Leitz G. Once-weekly dosing of 40,000 U epoetin alfa is as effective as thrice-weekly dosing among HIV+ patients [abstr]. In: Program and abstracts of the 41st interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, December 16-19, 2001. Washington, DC: American Society for Microbiology, 2001:322.
19. Moore RD. Anemia and human immunodeficiency virus disease in the era of highly active antiretroviral therapy. Semin Hematol 2000;37(suppl 6):18-23.
20. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992;41(RR-17):1-19.
21. Semba RD, Shah N, Vlahov D. Improvement of anemia among HIV-infected injection drug users receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001;26:315-19.
22. Moore RD, Forney D. Anemia in HIV-infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002;29:54-7.
23. Means RT. The anemia of chronic disorders. In: Lee GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM, eds. Wintrobe's clinical hematology, 10th ed. Baltimore: Williams & Wilkins, 1999:1011-18.
24. Kreuzer KA, Rockstroh JK. Pathogenesis and pathophysiology of anemia in HIV infection. Ann Hematol 1997;75:179-87.
25. Levine AM. Anemia, neutropenia and thrombocytopenia: pathogenesis and evolving treatment options in HIV-infected patients, Available from http://www.medscape.com/view program/669_pnt. Accessed August 15, 2002.
26. Volberding PV, Consensus statement: anemia in HIV infection-current trends, treatment options and practice strategies. Clin Ther 2000;22:1004-20.
27. Liebman HA, Cooley TP, Levine AM. The acquired immunodeficiency syndrome. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U, eds. Williams hematology 6th ed. New York: McGraw-Hill, 2001:985-92.
28. Janco RL. Hematologic aspects of acquired immunodeficiency disease. In: Lee GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM, eds. Wintrobe's clinical hematology, 10th ed. Baltimore: Williams & Wilkins, 1999:1956-9.
29. Division of AIDS. Table for grading severity of adult adverse experiences. Bethesda, MD: National Institute of Allergy and Infectious Diseases, Division of AIDS, August 1992.
30. National Comprehensive Cancer Network. Anemia: clinical practice guidelines in oncology. JNCCN 2003;1(suppl 1):2-13.
31. Lundgren JD, Mocroft A, Gatell JM, et al. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. J Infect Dis 2002;185:178-87.
32. McArthur JC, Hoover DR, Bacellar H, et al. Dementia in AIDS patients: incidence and risk factors. Neurology 1993;43: 2245-52.
33. Breitbart W, McDonald MV, Rosenfeld B, Monkman ND, Passik S. Fatigue in ambulatory AIDS patients. J Pain Symptom Manage 1998;15:159-67.
34. Groopman JE. Fatigue in cancer and HIV/AIDS. Oncology 1998;12:335-44.
35. Volberding P. The impact of anemia on quality of life in human immunodeficiency virus-infected patients. J Infect Dis 2002;185(suppl 2):110-14.
36. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998;25(suppl 7):43-6.
37. Barroso J. A review of fatigue in people with HIV infection. J Assoc Nurses AIDS Care 1999;10:42-9.
38. Claster S. Biology of anemia, differential diagnosis and treatment options in human immunodeficiency virus infection. J Infect Dis 2002;185(suppl 2):105-9.
39. Audet AM, Goodnough LT. Practice strategies for elective red blood cell transfusion. Ann Intern Med 1992;116:403-6.
40. Jain R. Use of blood transfusion in management of anemia. Med Clin North Am 1992;76:727-44.
41. American Society of Anesthesiologists. Practice guidelines for blood component therapy: a report by the American Society of Anesthesiologists task force on blood component therapy. Anesthesiology 1996;84:732-47.
42. Expert Working Group. Guidelines for red blood cell and plasma transfusion for adults and children. Can Med Assoc J 1997;156(suppl 11):1-24.
43. Moor ACE, Dubbelman TMAR, VanSteveninck J, Brand A. Transfusion-transmitted diseases: risks, prevention and perspectives. Eur J Haematol 1999;62:1-18.
44. Mudido PM, Dorazio GD, Yen-Lieberman B, et al. Human immunodeficiency virus type 1 activation after blood transfusion. Transfusion 1996;36:860-5.
45. Groopman JE. Impact of transfusion on viral load in human immunodeficiency virus infection. Semin Hematol 1997; 34(suppl 2):27-33.
46. Brunson ME, Alexander JW. Mechanisms of transfusion-induced immunosuppression. Transfusion 1990;30:651-8.
47. Kirkley SA. Proposed mechanisms of transfusion-induced immunosuppression. Clin Diagn Lab Immunol 1999;6:652-7.
48. Ortho Biotech Inc. Procrit (epoetin alfa) package insert. Raritan, NJ; 2000.
49. Sifton DW, ed. Drug topics red book. Montvale, NJ: Thomson Medical Economics, 2002.
50. Amgen, Inc. Aranesp (darbepoetin) package insert. Thousand Oaks, CA; 2002.